A Phase 3 Study of Ersodetug in Patients With Tumor Hyperinsulinism
Public ClinicalTrials.gov record NCT06881992. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3, Single-Arm, Open-label, Pivotal Study to Evaluate the Efficacy and Safety of Ersodetug Compared to Baseline in Patients With Inadequately Controlled Hypoglycemia Due to Tumor Hyperinsulinism (Tumor HI)
Study identification
- NCT ID
- NCT06881992
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Rezolute
- Other
- Enrollment
- 16 participants
Conditions and interventions
Conditions
Interventions
- Ersodetug Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 15, 2025
- Primary completion
- Aug 31, 2027
- Completion
- Aug 31, 2027
- Last update posted
- May 7, 2026
2025 – 2027
United States locations
- U.S. sites
- 8
- U.S. states
- 8
- U.S. cities
- 8
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Investigative Site | Chicago | Illinois | 60637 | Recruiting |
| Investigative Site | Bethesda | Maryland | 20892 | Not yet recruiting |
| Investigative Site | Boston | Massachusetts | 02114 | Recruiting |
| Investigative Site | Rochester | Minnesota | 55905 | Recruiting |
| Investigative Site | New York | New York | 10021 | Recruiting |
| Investigative Site | Canton | Ohio | 44718 | Recruiting |
| Investigative Site | Portland | Oregon | 97239 | Recruiting |
| Investigative Site | Houston | Texas | 77030 | Not yet recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 5 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06881992, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 7, 2026 · Synced May 9, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06881992 live on ClinicalTrials.gov.